

Description of Additional Supplementary Files

File Name: Supplementary Data 1

Description: Characteristics of MDS patients treated with venetoclax-based therapy at the time of progression after HMA therapy (n=28).

File Name: Supplementary Data 2

Description: Characteristics of patients with "CMP pattern" MDS (n=10) who failed venetoclaxbased therapy.

File Name: Supplementary Data 3

Description: Characteristics of MDS patients at the time of enrollment in clinical trials of venetoclax-based therapy regardless of prior therapies (n=53)

File Name: Supplementary Data 4

Description: Summary of mutations in patients with secondary (UPN#1, UPN#2, UPN#11) and primary (UPN#8, UPN#9, UPN#12) failure to venetoclax-based therapy